A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

NCT02365662 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

46

Enrollment

INDUSTRY

Sponsor class

Stopped Safety

Conditions

Head and Neck Squamous Cell Carcinoma
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Colorectal Carcinoma
Glioblastoma Multiforme

Interventions

DRUG: ABBV-221

Sponsor

AbbVie